Logo 1 Logo 2

Clinical Trial Details

Trial ID: L6637
Source ID: NCT02903511
Associated Drug: Metformin
Title: Feasibility Study of Metformin Therapy in ADPKD
Acronym:
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT02903511/results
Conditions: Polycystic Kidney, Autosomal Dominant
Interventions: DRUG: Metformin|DRUG: Placebo
Outcome Measures: Primary: Safety and Tolerability of Metformin, Percentage of participants who at the end of 12 months are still prescribed the full randomized dose of metformin or placebo, and the percentage of participants who are prescribed at least 50% of the randomized dose, 12 months | Secondary: Change in Total Kidney Volume, Total kidney volume will be measured by MRI (magnetic resonance imaging) at baseline and at 12 months. Percentage change from baseline in height-adjusted total kidney volume is reported., 12 months|Change in Kidney Function, Estimated glomerular filtration rate (eGFR) will be calculated from serum creatinine measurements at baseline and after 3, 6, 9 and 12 months. Change from baseline at 12 months is reported., 12 months|Rate of Serious Adverse Events (SAE), Serious adverse events occurring from the time of signing informed consent until the end of the study will be monitored in both treatment arms, 12 months
Sponsor/Collaborators: Sponsor: University of Colorado, Denver | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Gender: ALL
Age: ADULT
Phases: PHASE2
Enrollment: 56
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2016-11
Completion Date: 2020-08-17
Results First Posted: 2021-09-05
Last Update Posted: 2021-09-05
Locations: University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, 80045, United States
URL: https://clinicaltrials.gov/show/NCT02903511